Chengdu Kanghua Biological Products Co Ltd Class A 300841
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ¥55.11
- Day Range
- ¥58.12–65.98
- 52-Week Range
- ¥44.01–84.05
- Bid/Ask
- ¥65.83 / ¥65.84
- Market Cap
- ¥8.86 Bil
- Volume/Avg
- 8.3 Mil / 1.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- 12.11
- Price/Sales
- 4.36
- Dividend Yield (Trailing)
- 3.63%
- Dividend Yield (Forward)
- 3.63%
- Total Yield
- 3.63%
Company Profile
Chengdu Kanghua Biological Products Co Ltd is engaged in research, development, production, sales and technical services of biological products for prevention, and the existing products include Group ACYW135 Meningococcal Polysaccharide Vaccine-Maikexin, Rabies Vaccine (human diploid cell) for Human Use, freeze-dried - HDCV. The company's products include ACYW135 Meningococcal Polysaccharide Vaccine; and Rabies Vaccine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 672
- Website
- https://www.kangh.com
Comparables
Valuation
|
Metric
|
300841
|
301207
|
430047
|
|---|---|---|---|
Price/Earnings (Normalized) | 12.11 | 15.59 | — |
Price/Book Value | 2.16 | 1.84 | 9.30 |
Price/Sales | 4.36 | 4.74 | 44.84 |
Price/Cash Flow | 10.11 | 11.51 | — |
Price/Earnings
300841
301207
430047
Financial Strength
|
Metric
|
300841
|
301207
|
430047
|
|---|---|---|---|
Quick Ratio | 4.18 | 2.85 | 3.53 |
Current Ratio | 4.57 | 3.42 | 3.87 |
Interest Coverage | 124.81 | 149.96 | −127.19 |
Quick Ratio
300841
301207
430047
Profitability
|
Metric
|
300841
|
301207
|
430047
|
|---|---|---|---|
Return on Assets (Normalized) | 15.47% | 9.24% | −9.36% |
Return on Equity (Normalized) | 18.16% | 11.52% | −15.90% |
Return on Invested Capital (Normalized) | 17.07% | 10.82% | −13.55% |
Return on Assets
300841
301207
430047
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Yxybtwgvz | Dbv | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jzkptjcs | Nvbvft | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gwjdxnhl | Bvvhpj | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xmtkzfwl | Vnhnpk | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Sympnth | Pltzc | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Gqmhnjml | Jfg | $28.1 Bil | |||
| Moderna Inc
MRNA
| Whqrjlpw | Nqm | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Fkrqmsh | Pmzdj | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Jmddsdb | Kvvvvl | $13.4 Bil | |||
| Incyte Corp
INCY
| Jcthhdyl | Tbncn | $12.7 Bil |
United States